An RNA platform for diseases of aberrant DNA methylation
Specific RNAs can bind and inhibit DNMT1, the enzyme that methylates DNA. Aptadir builds on that discovery to switch silenced genes back on, globally or one locus at a time.
The problem
Aberrant methylation of certain genes by DNMT1 can cause abnormal cell development and lead to disease. Current DNMT1 inhibitors act briefly, carry significant toxicity and are not gene specific.
The discovery
Di Ruscio and colleagues showed in Nature (2013) that DNMT1-interacting RNAs, or DiRs, prevent DNA methylation and gene silencing in a locus-specific manner by binding and inhibiting DNMT1.
aptaDiR, global inhibition
Modified short RNA oligonucleotides achieve potent sequestration of DNMT1 without the cell toxicity of commercially available drugs.
captaDiR, locus-specific inhibition
Fusing the aptaDiR with a gene-specific sequence gives a high level of specificity within the targeted locus.
Where gene-specific DNMT inhibition could apply
Cancer
Lung (RASSF1, ESR1, MGMT), breast (BRCA1, CDH1, MGMT, GSTP1, ESR1), colon (P16, MGMT, GSTP1), leukemia (P15, DAPK1, CDH1, ESR1), prostate (GSTP1), retinoblastoma (RB1).
Genetic diseases
Fragile X syndrome (FMR1), myotonic dystrophy (DMPK), Prader-Willi syndrome (IPW), ALS (C9orf72), Lynch syndrome (MLH1/EPM2AIP1).
Neurological disorders
Alzheimer's disease (NEP).
Autoimmune diseases
Rheumatoid arthritis (SAT2, SAT3).
Publications
- 2023
Targeted systematic evolution of an RNA platform neutralizing DNMT1 function and controlling DNA methylation
Esposito CL, Autiero I, Sandomenico A, et al., Di Ruscio A. Nature Communications
- 2021
Pseudogene-mediated DNA demethylation leads to oncogene activation
Kwon J, Liu YV, Gao C, et al., Di Ruscio A, Tay Y, Chai L, Tenen DG. Science Advances
- 2020
Targeted intragenic demethylation initiates chromatin rewiring for gene activation
Liu YV, Bassal MA, Lin QXX, et al., Di Ruscio A, Tenen DG. bioRxiv
- 2013
DNMT1-interacting RNAs block gene-specific DNA methylation
Di Ruscio A, Ebralidze AK, Benoukraf T, Amabile G, et al., Tenen DG. Nature
Partners and investors
For partnering, licensing or investment conversations, write to the team in Milan.
Contact the teamThe people behind DiRs
An international group of scientists in RNA and DNA biology, leukaemia and oligonucleotide therapeutics.
Meet the team